Introduction {#Sec1}
============

The identification and avoidance of cerebral hypoxia/ischaemia is a central tenet of contemporary neurocritical care, and near-infrared spectroscopy (NIRS) has a potential monitoring role in this regard. However, whilst a plethora of studies describe the use of "cerebral oximeter" devices---which express absolute scaled concentrations of oxyhaemoglobin and deoxyhaemoglobin (\[HbO~2~\] and \[HHb\], respectively) in the form of a combined regional haemoglobin oxygen saturation---few studies outside the context of cardiopulmonary bypass link brain desaturation with neurological outcome or support the routine clinical use of such devices \[[@CR1]\].

Cytochrome *c* oxidase (CCO) is the terminal electron acceptor in the mitochondrial electron transport chain and responsible for 95% of cellular oxygen utilisation. Like haemoglobin, the oxidised and reduced forms of CCO have characteristic absorption spectra within the NIR band; these can be measured as the difference spectrum of oxidised--reduced CCO. However, changes in optical scattering and pathlength could potentially confound the accurate measurement of oxidised--reduced CCO concentration (\[oxCCO\]) in vivo \[[@CR2]\].

The aim of this study is to measure optical scattering, pathlength and changes in chromophore concentration in a cohort of brain-injured patients during normobaric hyperoxia (NBH).

Methods {#Sec2}
=======

After approval by the institutional Research Ethics Committee and representative consent, recordings were carried out in ten sedated, mechanically ventilated acute brain-injured patients on the neurocritical care unit. These patients were subjected to NBH protocol, which consisted of a 60-min epoch of baseline recording, followed by 60-min epochs where the inspired fraction of oxygen (FiO~2~) was increased to 60% and then 100%, followed by a final 30-min epoch where FiO~2~ was returned to baseline values. In patients with a baseline FiO~2~ of ≥50%, the 60% FiO~2~ epoch was omitted.

Systemic physiological monitoring included arterial blood pressure (ABP), pulse oximetry and intermittent measurement of arterial blood gases (ABGs)---including partial pressures of oxygen and carbon dioxide (PaO~2~ and PaCO~2~, respectively). Cerebral monitoring was positioned ipsilaterally to the more injured hemisphere and included transcranial Doppler (TCD) ultrasonography measurement of middle cerebral artery flow velocity (Vmca) (DWL Doppler Box, Compumedics Germany), measurement of the lactate--pyruvate ratio (LPR) by cerebral microdialysis (Dipylon Medical AB, Solna, Sweden) and continuous measurement of brain tissue oxygen tension (pbrO~2~) (Licox, Integra Neurosciences, Plainsboro, USA).

The hybrid optical spectrometer has been described in detail elsewhere \[[@CR3]\]. Briefly, it comprises two identical broadband spectrometers and a two-channel frequency domain (FD) spectrometer capable of absolute measurements of optical absorption and scattering coefficients (*μ* ~a~ and *μ* ~s~, respectively) at 690, 750, 790 and 850 nm. \[HHb\], \[HbO~2~\] and \[oxCCO\] were calculated using the UCLn algorithm \[[@CR4]\], fitting to changes in NIR attenuation from 780 to 900 nm. Differential pathlength factor (DPF) was derived from *μ* ~a~ and *μ* ~s~ measured at 790 nm during the baseline period of recording, with additional correction applied for the wavelength dependence of pathlength \[[@CR5]\]. Optodes were placed in the mid-pupillary line on the forehead, ipsilateral to the TCD and invasive monitoring. Chromophore concentrations derived from the 35 mm source--detector separation are presented.

Cerebral LPR was measured at 15-min intervals and ABGs at 30-min intervals. The remaining systemic, cerebral and NIRS variables were synchronised and monitored continuously, with the mean value from a noise-free window comprising ≥50% of each entire epoch used for subsequent analysis and reporting.

All values are reported as median  ±  interquartile range (IQR) except where otherwise stated. Probability was calculated using a Wilcoxon signed-rank test comparing the difference between the initial baseline and subsequent study epochs. A Bonferroni correction for repeated measures was applied and *p*  \<  0.017 defined as the level of statistical significance.

Results {#Sec3}
=======

Patient demographics are summarised in Table [10.1](#Tab1){ref-type="table"}. The NBH protocol induced significant changes in paO~2~and pbrO~2~, but not in paCO~2~ or Vmca (Table [10.2](#Tab2){ref-type="table"}).Table 10.1Data on patient demographicsPatient demographicsAge (range)45.5 (23--74)Sex7 Females, 3 malesPathology4 Traumatic brain injury, 6 subarachnoid haemorrhageMedian Admission Glasgow Coma Score (IQR)7.5 (4--8) Table 10.2Median (IQR) values for monitored physiological variables during four phases of experimentBaselineFiO~2~ 60%FiO~2~ 100%Return to baselineABP (mmHg)89.9\
(81.4--95.2)94.6\
(82.9--99.7)95.2\
(90.7--97.1)90.7\
(84.3--93.2)paO~2~ (kPa)13.9\
(11.7--18.1)*26.6\**\
*(25.8--31.1)52.9\**\
*(49.2--57.0)*11.8\
(10.9--14.4)paCO~2~ (kPa)4.8\
(4.6--5.0)5.0\
(4.8--5)4.8\
(4.6--4.9)5.1\
(4.7--5.5)pbrO~2~ (kPa)2.8\
(1.6--3.4)*4.0\*(2.5--4.7)7.4\*(5.6--8.6)*3.5(1.7--4.7)Vmca (cm s^−1^)54.3(51.3--79.6)56.2(48.7--84.7)54.3(50.3--83.1)57.1(51.8--86.1)Values showing a statistically significant difference from initial baseline are italicised**\*** *p*  \<  0.01

The FD spectrometer failed to collect data at 750 nm in two patients and at 790 and 850 nm in one patient. The remaining data revealed no significant change observed in the values of *μ* ~s~ and DPF at any wavelength (Table [10.3](#Tab3){ref-type="table"}).Table 10.3Median (IQR) values for measured optical scattering coefficient (*μ* ~s~) and differential pathlength factors at four wavelengthsBaselineFiO~2~ 60%FiO~2~ 100%Return to baseline*μ* ~s~ 690 nm (cm^−1^)10.8(9.05--10.8)10.6(10.1--12.3)10.5(9.74--12.4)10.3(9.39--12.5)*μ* ~s~ 750 nm (cm^−1^)9.93(9.02--10.2)10.0(9.04--10.5)9.76(9.00--10.6)9.89(8.99--10.7)*μ* ~s~ 790 nm (cm^−1^)9.48(8.8--9.75)9.49(8.59--11.5)9.25(8.25--11.8)9.10(7.44--11.8)*μ* ~s~ 850 nm (cm^−1^)9.10(9.0--9.70)9.40(8.76--9.80)9.36(8.68--9.54)9.35(8.9--9.4)DPF 690 nm8.40(8.33--8.71)8.634(8.52--9.44)8.88(8.49--9.57)8.54(8.03--9.37)DPF 750 nm8.15(7.9--8.24)8.12(7.76--8.44)8.32(7.96--9.11)8.15(7.87--9.05)DPF 790 nm8.14(8.12--8.28)8.24(7.91--8.49)8.21(7.92--8.81)7.98(7.89--8.63)DPF 850 nm8.07(8.06--8.52)8.00(7.73--8.40)7.94(7.66--8.37)8.00(7.83--8.31)No variable showed statistically significant variation from baseline

Changes in chromophore concentration are shown in Fig. [10.1](#Fig1){ref-type="fig"}. There was a statistically significant increases in \[HbO~2~\] and \[oxCCO\] and decreases in \[HHb\] during NBH (∆\[HbO~2~\]: +0.36 and +0.58 μmol l^−1^; ∆\[HHb\]: −0.54 and −1.56 μmol l^−1^; ∆\[oxCCO\]: +0.15 and +0.28 μmol l^−1^ during 60% FiO~2~ and 100% FiO~2~ phases, respectively). The baseline median LPR was 24.4 (IQR 22.2--25.7) and showed a statistically significant decrease during NBH (∆LPR: −2.8 and −3.3 during 100% FiO~2~ and return-to-baseline epochs, respectively) and a nonsignificant decrease of −0.8 during the 60% FiO~2~ phase (*p*  \<  0.019).Fig. 10.1Changes in: (**a**) oxyhaemoglobin (*open circles*) and deoxyhaemoglobin (*solid circles*); (**b**) microdialysate lactate--pyruvate ratio; (**c**) haemoglobin difference; (**d**) oxidised--reduced cytochrome *c* oxidase for each phase of study. *B* baseline, *60%* FiO~2~ 60%, *100%* FiO~2~ 100%, *RTB* return to baseline. \**p*  \<  0.017; \*\**p*  \<  0.01 comparing study epoch to initial baseline

Discussion {#Sec4}
==========

We have used a hybrid optical spectrometer to measure optical scattering, pathlength, changes in oxy- and deoxyhaemoglobin concentrations and changes in CCO oxidation state during NBH in ten critically ill brain-injured patients.

Changes in chromophore concentration, and in particular \[oxCCO\], have been reported before in a clinical context: the pattern of \[oxCCO\] change has been related to clinical outcome following cardiopulmonary bypass \[[@CR6]\] and our group have previously demonstrated an increase in \[oxCCO\] with NBH \[[@CR7]\] and heterogeneous changes with hypercapnoea \[[@CR8]\]. However, changes in optical scattering and pathlength have been proposed as key confounding factors in the measurement of \[oxCCO\] \[[@CR2]\] and the effects of changes in pathlength and scattering on \[oxCCO\] measurement have been hitherto unknown.

We have adopted a novel approach that combines simultaneous measurement of optical scattering and pathlength in addition to measurement of changes in chromophore concentration and LPR. The concordance between the microdialysis and \[oxCCO\], combined with the absence of changes in either *μ* ~s~ or pathlength, suggests that scattering and pathlength changes do not confound the measurement of chromophore concentration and that the change in \[oxCCO\] seen during NBH therefore represents an actual increase in mitochondrial aerobic metabolism.

The pattern of chromophore concentration change that we have observed during NBH is similar to that previously reported by our group using different apparatus in a cohort patients who had a similar median age and admission GCS, but had a primary diagnosis of traumatic brain injury rather than the mixed group of traumatic and vascular brain injuries reported in this study. The magnitude of \[HbO~2~\] increase, however, was smaller in our cohort than that previously reported. The reasons for this are unclear, but may include pathophysiological and instrumentation factors. Interpreting the physiological mechanisms underlying the increase in \[oxCCO\] in response to NBH is challenging, but may be enhanced by the use of a mathematical model of the cerebral circulation and metabolism \[[@CR9]\]. Further work is required to elucidate the relationship between \[oxCCO\] and changes in cerebral oxygen availability and may aid in the translation of NIRS-derived measurement of \[oxCCO\] from a research to a clinical tool.

The original version of this chapter was revised. An erratum to this chapter can be found at DOI 10.1007/978-1-4614-4989-8_53
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